[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Hospital of Traditional Chinese Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":219},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,70,95,118,145,167,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643394","fire-needling-plus-filiform-needling-for-chronic-migraine-with-comorbid-tension-type-headache-100643394",false,"NCT07633522","Fire Needling Plus Filiform Needling for Chronic Migraine With Comorbid Tension-Type Headache","Clinical Research on Fire Needling Combined With Filiform Needling for Chronic Migraine With Comorbid Tension-type Headache","Inclusion Criteria:\n\n* Meets the diagnostic criteria for tension-type headaches with pericranial tenderness;\n* Meets the diagnostic criteria for chronic migraine;\n* 18 years ≤ age ≤ 65 years;\n* Has sufficient understanding to complete the necessary examinations and tests for the study;\n* Voluntarily joins this study and signs the informed consent form.\n\nExclusion Criteria:\n\n* Patients complicated with cluster headache or other primary headaches;\n* Patients with secondary headaches caused by intracranial space-occupying lesions, cranial infections, etc.;\n* Patients complicated with severe heart, liver or kidney impairment, coagulation disorders, infections, severe immunocompromise, or allergic predisposition;\n* Patients with alcohol or drug dependence;\n* Patients who are unable to cooperate with acupuncture treatment;\n* Women who are planning pregnancy, pregnant or breastfeeding;\n* Patients who have received acupuncture treatment within 3 months prior to enrollment.","ALL","18 Years","65 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"NA","The investigators conducted a multicenter, prospective, randomized controlled clinical study to learn whether fire needling combined with filiform needling applied to pericranial muscle tenderness areas can effectively treat chronic migraine with comorbid tension-type headache. The study will also evaluate the safety and long-term efficacy of this therapy. Its main target questions include:\n\n1. Can fire needling significantly reduce the number of headache days per month?\n2. What is the effect of this therapy on headache intensity, emotional symptoms, and quality of life? The investigators will compare \"fire needling at pericranial tender points plus conventional filiform needling\" versus \"conventional filiform needling alone\" to verify whether the key technique of fire needling plus conventional filiform needling provides unique additive value.\n\nParticipants will:\n\n1. Receive treatment twice per week for 8 weeks (either in the experimental group or the control group)，attend a follow-up visit at week 24 after enrollment\n2. Keep a headache diary (recording headache frequency, pain intensity, duration, associated symptoms, etc.)\n3. Regularly complete assessments of emotional status, quality of life, and number of pericranial tender points",[27,28],"Chronic Migraine","Tension-type Headache",[30,31,32,33],"fire needling","filiform needling","chronic migranie","tension-type headache","NOT_YET_RECRUITING","2026-06-04",{"date":37,"type":38},"2026-06-08","ACTUAL",{"date":40,"type":21},"2026-08",{"date":42,"type":21},"2028-12",{"name":44,"class":45},"Beijing Hospital of Traditional Chinese Medicine","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100638390","phase-3-phase-iii-clinical-trial-of-changjian-capsules-in-the-treatment-of-irritable-bowel-syndrome-with-predominant-diarrhea-liver-qi-invading-spleen-syndrome-100638390","NCT07610434","Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)","Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial on the Efficacy and Safety of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)","Inclusion Criteria:\n\n1. Meet the Western medicine diagnostic criteria for diarrhea-predominant irritable bowel syndrome;\n2. Meet the Traditional Chinese Medicine syndrome differentiation criteria for liver Qi invading the spleen;\n3. Aged ≥18 and ≤65 years, regardless of gender;\n4. Record daily the most severe abdominal pain, bloating, and abdominal discomfort NRS scores for the last week of the run-in period. At least one of these three items must meet the weekly average NRS score criterion (the weekly average of abdominal pain NRS is calculated as: total weekly score of abdominal pain NRS on days with Bristol Stool Form Scale type 6 or 7 stools \u002F actual number of days with Bristol type 6 or 7 stools in that week; the average values for the other two items are calculated similarly) ≥3 points (11-point Numerical Rating Scale, NRS-11); meanwhile, for stool form, during the last week of the run-in period, there must be at least 2 days in which each day has at least one bowel movement of Bristol type 6 or 7;\n5. Self-Rating Anxiety Scale (SAS) \\\u003C60 points and Self-Rating Depression Scale (SDS) \\\u003C63 points;\n6. Have a colonoscopy result showing no obvious abnormalities (including diverticula or chronic inflammation) or colon polyps, based on colonoscopy results within 12 months prior at a tertiary hospital: 1.Colonoscopy results are normal with no organic changes; 2. Colonoscopy report shows minor abnormalities such as hemorrhoids or colonic polyps (diameter ≤5mm and number ≤3), which the investigator deems eligible for inclusion; 3. Previous colonoscopy reported colonic polyps with diameter \\>5mm or number \\>3, but after endoscopic treatment within 6 months prior to screening, remaining polyps are ≤5mm in diameter and ≤3 in number, deemed eligible by the investigator;\n7. Agree to participate in this clinical trial and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Individuals with fewer than 3 spontaneous bowel movements per week during the induction period;\n2. Individuals with stool consistency of type 1 or 2 (Bristol Stool Form Scale) on at least 2 days per week during the induction period;\n3. Individuals confirmed to have infectious diarrhea, inflammatory bowel disease, parasitic infection, positive fecal occult blood tests and considered to have gastrointestinal bleeding (excluding hemorrhoids), colorectal tumors, malabsorption syndrome, lactose intolerance (based on medical history), and diarrhea caused by systemic diseases;\n4. Individuals who have used other medications for irritable bowel syndrome within 1 week prior to screening;\n5. Individuals with non-IBS-D or other organic gastrointestinal lesions (excluding superficial gastritis, grade I erosive gastritis, or chronic atrophic gastritis found on endoscopy but deemed by the investigator to be eligible for inclusion (e.g., no mucosal erosion or bleeding observed endoscopically, and the patient has no upper abdominal fullness, upper abdominal pain, or acid reflux)), or other organic lesions that the investigator judges may cause abdominal pain, bloating, or discomfort;\n6. Individuals with diabetes, hyperthyroidism, or serious primary diseases of the cardiovascular, cerebrovascular, liver, kidney, hematopoietic systems, or other serious diseases affecting survival (e.g., tumors), abnormal liver and kidney function (AST, ALT \\> 1.5 times the upper limit of normal reference range, Scr above the upper limit of normal reference range), and clinically significant ECG abnormalities;\n7. Individuals with other mental disorders (excluding mild anxiety or depression);\n8. Individuals with a history of gastrointestinal surgery (excluding appendectomy or intestinal polyp removal);\n9. Individuals who, within 2 weeks prior to screening, are using or need to continue using medications that may affect gastrointestinal function (anticholinergic drugs, 5-HT3 receptor antagonists, antidiarrheal drugs, antacids, prokinetic drugs, antidepressants (fluoxetine for at least 28 days), anti-anxiety drugs, intestinal microbiota regulators, traditional Chinese medicine decoctions, etc.);\n10. Individuals allergic to 3 or more medications or foods, or known allergies to Xiangjie Capsules and its components, as well as emergency medication Pivabromium tablets;\n11. Individuals who took emergency medication (Pivabromium tablets) during the last week of the induction period;\n12. Individuals who took prohibited medications during the induction period;\n13. Individuals suspected of or confirmed with a history of alcohol or drug abuse;\n14. Pregnant women, breastfeeding women, or women of childbearing age planning to conceive; or female participants of childbearing potential and male participants (whose partners are women of childbearing potential) who do not agree to voluntarily use effective contraception from screening to 3 months after the last dose;\n15. Individuals with cognitive impairment unable to provide fully informed consent;\n16. Individuals positive for hepatitis B surface antigen, HIV antibody, hepatitis C antibody, or syphilis treponemal antibody;\n17. Individuals who have participated in another clinical trial within the past month;\n18. Individuals known to have familial colorectal cancer syndrome;\n19. Individuals who, in the opinion of the investigator, have other factors making them unsuitable for inclusion.",{"count":55,"type":21},636,[57],"PHASE3","This trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase III clinical trial. Its purpose is to evaluate the efficacy and safety of Changji'an Capsules in subjects with diarrhea-predominant irritable bowel syndrome (liver-qi invading spleen syndrome) after 8 weeks of treatment.",[60],"IBS, Diarrhea Predominant","2026-05-22",{"date":63,"type":38},"2026-05-28",{"date":65,"type":21},"2026-05-31",{"date":67,"type":21},"2028-05-31",{"name":44,"class":45},29,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100566311","thread-embedding-acupuncture-therapy-for-weight-loss-100566311","NCT06653530","Thread Embedding Acupuncture Therapy for Weight Loss","Efficacy and Safety of Thread Embedding Acupuncture Therapy for Weight Loss in Adults with Overweight or Obesity","iSho","Inclusion Criteria:\n\n1. Body-mass index: a. BMI ≥ 28 kg\u002Fm2 or b. BMI ≥ 24 kg\u002Fm2 with the presence of at least one of the following weight-related complications (treated or untreated): diabetes, hypertension, lipid metabolism disorders, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, hyperuricemia, fatty liver;\n2. Male or female, age between 18 and 75 years at the time of signing informed consent;\n3. No history of receiving thread embedding treatment;\n4. History of at least one self-reported unsuccessful dietary effort and exercise program to lose body weight;\n5. Informed consent obtained.\n\nExclusion Criteria:\n\n1. A self-reported change in body weight ≥ 5 kg within 90 days before screening;\n2. Treatment with any medication for the indication of obesity within the past 90 days before Screening;\n3. Previous or planned (during the trial period) obesity treatment with surgery or a bodyweight loss device. However, the following were allowed: (1) liposuction and\u002For abdominoplasty, if performed more than 1 year before screening; (2) lap banding, if the band had been removed more than 1 year before screening; (3) intragastric balloon, if the balloon had been removed more than 1 year before screening; or (4) duodenal-jejunal bypass sleeve, if the sleeve had been removed more than 1 year before screening;\n4. Have obesity induced by other endocrinologic disorders (for example, Cushing Syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome);\n5. Uncontrolled thyroid disease, defined as thyroid stimulating hormone (TSH)\\>6.0 mIU\u002FL or \\\u003C0.35 mIU\u002FL as measured by the central laboratory at screening;\n6. Diagnosed with type 2 diabetes mellitus ≤180 days prior to the day of screening or those who have taken treatment with oral agents that were unstable (different drug(s), dose, or dosing frequency) within the 90 days prior to screening;\n7. Receipt of any acupuncture treatment for obesity within 90 days before screening;\n8. Participation in any structured, monitored weight-loss program within 90 days before screening;\n9. Active inflammatory bowel disease, celiac disease, chronic pancreatitis, or other disorder potentially causing malabsorption;\n10. Any of the following severe cardiovascular diseases: myocardial infarction, stroke, heart failure, symptomatic peripheral vascular diseases, or hospitalization for unstable angina or transient ischemic attack within the last 6 months prior to screening;\n11. History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed;\n12. Chronic respiratory, neurological, musculoskeletal or other disorders where, in the judgement of the investigator, participants would have unacceptable risk or difficulty in complying with the protocol;\n13. Surgery scheduled for the duration of the trial, except for minor surgical procedures, in the opinion of the investigator;\n14. Known or suspected abuse of alcohol or recreational drugs;\n15. Female who was pregnant, breast-feeding, or intended to become pregnant, or was of child-bearing potential and not using a highly effective contraceptive method;\n16. Known or suspected hypersensitivity to trial product or related products;\n17. Participation in another clinical trial within 90 days before screening;\n18. Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion might have jeopardised the participant's safety or compliance with the protocol.","75 Years",{"count":80,"type":21},400,[24],"Obesity is the most prevalent chronic disease worldwide, affecting approximately 800 million adults. Excess adiposity and its numerous complications, including cardiovascular disease and type 2 diabetes, impose a considerable economic burden and constitute major contributors to global morbidity and mortality. Treatments that result in substantial weight reductions may improve outcomes for people living with obesity. Thread embedding acupuncture which provides long-term acupoints stimulation may be an effective treatment option for obesity. However, effects of thread embedding on obesity remain uncertain because of the small sample sizes or other methodological limitations. The objective of this multi-center, randomized, sham-controlled trial is to assess the effect of thread embedding acupuncture for alleviating weight.",[84],"Obesity and Overweight","RECRUITING","2025-01-15",{"date":88,"type":38},"2025-01-16",{"date":90,"type":38},"2024-11-01",{"date":92,"type":21},"2026-10-31",{"name":44,"class":45},1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100572988","phase-3-xuanhuang-runtong-tablet-in-the-treatment-of-constipation-yin-deficiency-type-100572988","NCT06740422","Xuanhuang Runtong Tablet in the Treatment of Constipation (Yin-deficiency Type)","A Randomized, Double-blind, Placebo-controlled, Multicenter Phase Ⅲ Clinical Trial on the Efficacy and Safety of Xuanhuang Runtong Tablet in Treating Constipation (Yin-deficiency Type).","XHRT","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to enter the run-in period:\n\n1. Meeting the diagnostic criteria of traditional Chinese medicine (TCM) constipation;\n2. Meeting the TCM syndrome differentiation criteria of constipation with yin deficiency syndrome;\n3. Both males and females are eligible, aged between 18 and 70 years old (including 18 and 70);\n4. Willing to participate in the trial and sign the informed consent form.\n\nAt the end of the run-in period, subjects must meet all of the following criteria to enter the treatment period:\n\n1. Meeting the diagnostic criteria of TCM constipation;\n2. Meeting the TCM syndrome differentiation criteria of constipation with yin deficiency syndrome;\n3. The number of spontaneous bowel movements in the last week of the run-in period is less than 3.\n\nExclusion Criteria:\n\nSubjects with any of the following items cannot enter the run-in period\u002Ftreatment period:\n\n1. Subjects with constipation or severe anal diseases causing defecation disorders diagnosed by researchers due to rectal, colonic organic diseases (such as tumors, inflammatory bowel diseases, intestinal adhesions, colon tuberculosis, etc.);\n2. Subjects with constipation caused by central nervous system diseases (such as multiple sclerosis, Parkinson's disease, spinal cord injury, etc.) or muscle diseases (such as amyloidosis, dermatomyositis, etc.) known or identified as being caused by drugs;\n3. Subjects with colonoscopy results showing intestinal polyps \\> 0.5 cm or quantity \\> 3 (subjects with removed intestinal polyps are not excluded, but those with tubular adenoma accompanied by high-grade intraepithelial neoplasia or those who need to re-examine colonoscopy in the near future are excluded);\n4. Subjects who have taken drugs for treating constipation within 1 week before screening or within 5 half-lives (calculated according to the longer time);\n5. Subjects with severe heart, liver, kidney, brain, blood, metabolic and endocrine system diseases and unstable conditions requiring drug adjustment at any time, and patients with malignant tumors;\n6. Subjects who are evaluated by researchers as unable to cooperate with clinical trialists in terms of psychological, mental status or cognitive ability, language expression ability, etc. or have a history of severe mental illness, such as patients with severe depression and severe anxiety.\n7. Subjects who have had abdominal surgery within 3 months before screening or plan to have abdominal surgery during the trial period;\n8. Subjects with HbA1c \\> 8.5% at screening;\n9. Subjects with ALT or AST ≥ 1.5 times the upper limit of the normal value, or Scr \\> the upper limit of the normal value;\n10. Subjects with known or suspected allergies or severe adverse reactions to the components of Xuanhuang Runtong Tablets or Bisacodyl Enteric-coated Tablets, or with an allergic constitution (such as allergies to two or more drugs or foods);\n11. Subjects who have participated in other clinical trials and taken trial drugs within the past 3 months;\n12. Subjects with suspected or confirmed history of alcohol or drug abuse;\n13. Pregnant or lactating women; or female and male subjects of childbearing potential who are unwilling or unable to take effective contraceptive measures during the trial period;\n14. Subjects with other conditions that researchers consider inappropriate to participate in this trial.","70 Years",{"count":105,"type":21},300,[57],"This trial is a randomized, double-blind, placebo-controlled parallel-group, multicenter Phase III clinical trial. It is to evaluate the efficacy and safety of Xuanhuang Runtong Tablets in subjects with constipation (Yin-deficiency type) after 4 weeks of treatment.",[109],"Constipation","2024-12-14",{"date":112,"type":38},"2024-12-18",{"date":114,"type":21},"2024-12-15",{"date":116,"type":21},"2027-06-15",{"name":44,"class":45},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":125,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":94},"100572853","acupuncture-for-painful-temporomandibular-disorder-100572853","NCT06738667","Acupuncture for Painful Temporomandibular Disorder","Study on Imaging Characteristics and Predictive Radiology of Brain Network Regulation by Acupuncture in Patients with Painful Temporomandibular Disorders","Inclusion Criteria:\n\n1. Having a history of pain-related TMD for at least three months;\n2. Aged between 18 and 70 years;\n3. Voluntary participation in the trial with signed informed consent.\n\nExclusion Criteria:\n\n1. Having received occlusal splint, injection therapy, acupuncture, biofeedback, transcutaneous nerve stimulation, or TMD-specific medication (e.g., corticosteroids, benzodiazepines, sedative hypnotics, muscle relaxants, opioids, antidepressants, or anticonvulsants) for managing facial pain within one month before the screening period;\n2. Having suffered from pain of dental origin, trauma, sinus pathology, neuropathic origin, inflammatory systemic diseases and cancer;\n3. Having a history of rheumatoid arthritis;\n4. Presence of mental illness or substance abuse;\n5. Pregnant, lactating, or planning to become pregnant;\n6. Participants with common contra-indications for MRI such as claustrophobia or metal implants.",true,{"count":127,"type":21},48,[24],"Temporomandibular disorder (TMD) is a common musculoskeletal pain condition affecting the jaw, and acupuncture is often used for treatment, though its neurological mechanisms are unclear. This study investigates the neural mechanisms of acupuncture in TMD using functional MRI (fMRI), structural MRI (sMRI), and diffusion tensor imaging (DTI), alongside machine learning to predict treatment outcomes. This study aims to enhance understanding of acupuncture's effects on TMD and improve personalized treatment approaches.",[131],"Temporomandibular Disorders (TMD)",[133,134,135,136,137],"Temporomandibular disorders","Acupuncture","Magnetic resonance imaging","Randomized controlled trial","Protocol","2024-12-13",{"date":112,"type":38},{"date":141,"type":21},"2025-06-01",{"date":143,"type":21},"2026-12-31",{"name":44,"class":45},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":94},"100569487","critical-state-of-remission-recurrence-of-ulcerative-colitis-100569487","NCT06694883","Critical State of \"Remission-Recurrence\" of Ulcerative Colitis","Research on the Biological Basis of \"Disease-Syndrome-Formula\" in the Critical State of \"Remission-Recurrence\" of Ulcerative Colitis (Joint Application A)","CSRRUC","Inclusion Criteria:\n\n* Patients who meet the criteria based on the clinical characteristics of ulcerative colitis patients in the \"remission recurrence\" critical state, combined with clinical symptoms, are diagnosed with ulcerative colitis through imaging, endoscopy, laboratory, and histopathological examinations;\n* Patients with comprehensive laboratory testing indicators.\n\nExclusion Criteria:\n\n* Patients with incomplete case information records;\n* Patients who have not completed serological tests;\n* Complications including intestinal obstruction, intestinal perforation, toxic megacolon, and severe local stenosis;\n* Diagnosed or suspected patients with coexisting uncertain colitis, infectious or ischemic colitis;\n* Patients with coexisting local or systemic infections, any malignant diseases, or autoimmune diseases;\n* Merge primary diseases such as respiratory, circulatory, neurological, endocrine, and hematological disorders;\n* Individuals at risk of developing cancer;\n* regnant or lactating women.",{"count":154,"type":21},100,"OBSERVATIONAL","This study will recruit 100 patients with ulcerative colitis in remission for a 6-month non intervention follow-up observation. During the study, their conditions will be recorded truthfully, including general information, disease-related symptoms and signs, inflammatory bowel disease questionnaire, anxiety self-assessment scale, depression self-assessment scale, etc., every month. Collect blood, urine, and stool samples from patients every month for examination. Follow up for each subject until their condition recurs.",[158],"Ulcerative Colitis","2024-11-15",{"date":161,"type":38},"2024-11-19",{"date":163,"type":38},"2024-09-19",{"date":165,"type":21},"2025-05",{"name":44,"class":45},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":4},"100562688","effect-of-acupuncture-for-rapid-eye-movement-sleep-behavior-disorder-100562688","NCT06606418","Effect of Acupuncture for Rapid Eye Movement Sleep Behavior Disorder","Effect of Acupuncture for Rapid Eye Movement Sleep Behavior Disorder : a Randomized Controlled Trial","Inclusion Criteria:\n\n* (1) Patients who meet the diagnostic criteria of ICSD-3. To confirm this diagnosis, one of the following conditions must be met: ① The diagnosis is RBD after previous vPSG examination. ② Those who have not been diagnosed should fill in RBDQ-HK. If the score is greater than 20, it indicates possible RBD, and accept vPSG test to confirm the diagnosis.\n* (2)Patients belong to iRBD or secondary to the following three alpha-synuclein diseases: Parkinson\\'s disease\u002Fmultiple system atrophy\u002FLewy body dementia;\n* (3) ≥18 years of age, male or female;\n* (4) At least 2 episodes of RBD events in the past 2 weeks (recalled by the patient or described by family members), including: ① verbal behavior, such as Shouting and swearing; ② Physical movement behavior, such as waving arms, punching and kicking; ③Falling out of bed, dropping things around you, injuring yourself or others, which is speculated to be related to dreaming behavior;\n* (5) Volunteer subjects and sign informed consent;\n* (6) Can cooperate with the completion of this study.\n\nExclusion Criteria:\n\n* (1) During pregnancy or lactation;\n* (2) Patients with secondary RBD associated with narcolepsy or antidepressant use;\n* (3) Patients with severe anxiety, depression and other mental diseases, alcohol abuse and\u002For psychoactive drug use, drug abusers and dependents;\n* (4) Patients with serious underlying diseases, especially unstable diseases (such as malignant tumors, chronic obstructive pulmonary disease, unstable heart disease, etc.);\n* (5) Patients with coagulation dysfunction, skin infection or damage at the surgical site should not receive acupuncture.",{"count":175,"type":21},30,[24],"Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia that is characterized by abnormal behaviours occurring during REM sleep（a sleep stage）, often as dream enactments that can cause injury. Treatment options are limited. Pharmacological treatments include melatonin and clonazepam, but they have varying degrees of adverse reactions. Acupuncture is a green and safe means of treatment and has therapeutic value in sleep disorders. Using the theory of traditional Chinese medicine, the acupuncture treatment of RBD group points was formulated, and good clinical effect was obtained in the early clinical practice.This study was designed to explore the clinical efficacy of acupuncture in the treatment of RBD. Thirty patients with RBD who met the inclusion and exclusion criteria were randomly divided into acupuncture group and sham acupuncture group, and were subjected to a 2-week screening period, a 4-week treatment period, and a 2-week follow-up period.The investigators will primarily observe whether there is a reduction in the number of weekly RBD events recorded by the wCIRUS-RBD questionnaire before and after treatment, and the reduction in the RWA index recorded by video polysomnography (vPSG).",[179],"Rapid Eye Movement Sleep Behavior Disorder",[181,182,183,184],"Rapid eye movement sleep behaviour disorder(RBD)","acupuncture","randomized controlled trial","clinical research","2024-09-20",{"date":187,"type":38},"2024-09-23",{"date":189,"type":21},"2024-09-25",{"date":191,"type":21},"2025-04-30",{"name":44,"class":45},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":4},"100546521","phase-1-a-multicentre-randomized-controlled-clinical-study-on-the-chitosan-nanocrystalline-qinteng-huoxue-runji-ointment-therapy-for-psoriasis-with-blood-stasis-syndrome-100546521","NCT06396013","A Multicentre Randomized Controlled Clinical Study on the Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment Therapy for Psoriasis With Blood Stasis Syndrome.","Inclusion Criteria:\n\n1. Meets the diagnostic criteria of plaque psoriasis vulgaris;\n2. Meets the diagnostic criteria of plaque psoriasis with blood stasis syndrom;\n3. 18 ≤ age ≤65 , gender is not limited;\n4. Quiescent patients;\n5. Severity of the disease: mild to moderate lesions were 3≤PASI≤10, and 3≤BSA≤10;\n6. Volunteers can understand the research content and sign the informed consent voluntarily. The informed consent process complies with the provisions of the GCP.\n\nExclusion Criteria:\n\n1. psoriasis induced by drug factors; Combined with non-plaque psoriasis (i.e. guttate, joint, pustule, erythroderma, or other types of psoriasis); Skin lesions were found only in special parts of the face, scalp, nails, creases, glans, mucous membranes, palms and plantar.\n2. Received abiotic agents of systemic drug therapy within 4 weeks prior to randomization, including but not limited to systemic glucocorticoids, retinoids, methotrexate, and cyclosporine;\n3. Received biologics within 12 weeks or 5 half-lives prior to randomization (whatever is longer), including but not limited to interleukin antibodies (e.g. Usinumab, secuchiumab, etc.) and tumor necrosis factor a antagonists (e.g. Etanercepp, infliximab, adalimumab, etc.);\n4. Local topical psoriasis treatment, including retinoids, vitamin D3 derivatives, glucocorticoids, etc., had been received within 2 weeks before randomization;\n5. Use of physical therapy within 4 weeks before randomization, including phototherapy (such as UVB, PUVA), phototherapy combined therapy, bath therapy, etc.;\n6. systemic anti-infection therapy within 4 weeks prior to randomization; A recurrent, chronic, or active infection at baseline that the investigator determined would increase the subject's risk;\n7. with a serious, progressive, or uncontrolled disease, including but not limited to past or current autoimmune disease (such as: Rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc.) or diseases of the endocrine system, blood system, urinary system, hepatobiliary system, respiratory system, nervous system, mental system, cardiovascular system, gastrointestinal system or infectious diseases, malignant tumors; A history of drug abuse, alcohol\u002Fdrug abuse;\n8. Patients with serum creatinine higher than the upper limit of normal, glutamic pyruvic transaminase or glutamic oxalacetic transaminase level ≥1.5 times the upper limit of normal;\n9. Patients who have participated in clinical trials and used investigational drugs within 1 month;\n10. Patients who are allergic to known components of the trial intervention;\n11. The patient (including the partner) has a pregnancy plan from 2 weeks before the first dose to 1 month after the last dose or is unwilling to take effective contraceptive measures during pregnancy or lactation;\n12. There are circumstances that other investigators consider unsuitable for study participation, such as subjects with other skin problems that hinder the evaluation of psoriasis, potential compliance problems, inability to complete all examinations and evaluations as required by the protocol, and uncontrollable risks to study participation.",{"count":200,"type":21},96,[202],"PHASE1","Background: Psoriasis is one of the hot spots in the field of skin disease prevention and treatment, and TCM topical preparations have unique advantages in the treatment of psoriasis. The Qinteng Huoxue prescription series of TCM topical preparations created by Professor Sun Liyun have been observed to be effective in clinical practice in the treatment of psoriasis, but there is no multi-center clinical trial for blood stasis syndrome. In addition, the TCM topical preparations has the disadvantages of large particle diameter and unfavorable penetration of skin barrier.\n\nObjective: In this study, chitosan nanocrystalline drug delivery system was used to prepare Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment, and the efficacy and safety of Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment in the intervention of psoriasis with blood stasis syndrome was investigated through multi-center, randomized, double-blind, self-controlled bilateral skin lesions and placebo-controlled clinical trials.\n\nMethods: A total of 96 patients with plaque psoriasis with blood stasis syndrome of were enrolled in 4 research centers, and bilateral symmetrical rashes on limbs or trunk were selected, and randomly divided into experimental group and control group. The experimental group received topical Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment, twice a day for 12 weeks, and the control group received topical placebo twice a day for 12 weeks, and two follow-up visits were performed at the 16th and 20th week.\n\nResults Indicators: The main efficacy indicators were targeted psoriasis area and severity index (tPASI), and the secondary efficacy indicators included: Psoriasis physician global assessment (PGA), target lesion area, numerical rating scale (NRS), TCM syndrome score, dermatology life quality index (DLQI), MOS 36 item short from health survey (SF-36)), and the morphology and number of vascular globules under dermoscopy. tPASI, PGA, target lesion area, NRS were assessed at baseline, at 2, 4, 6, 8, 10, 12 weeks of treatment, and at 16 and 20 weeks of follow-up. TCM syndrome score, DLQI, SF-36, and dermoscopy were assessed at baseline, 12 and 20 weeks. Safety assessment includes vital signs monitoring, blood routine, urine routine, liver and kidney function tests, and adverse events and adverse reactions. SPSS 20.0 was used for data analysis.",[205],"Plaque Psoriasis",[207,208,209,210,183],"Plaque psoriasis","blood stasis syndrome","Qinteng Huoxue Runji Ointment","chitosan","2024-04-29",{"date":213,"type":38},"2024-05-02",{"date":215,"type":21},"2024-06-01",{"date":217,"type":21},"2026-07-31",{"name":44,"class":45},""]